Lu Peng sold $610K of PHVS

Lu Peng (President) sold 15,000 shares of Pharvaris N.V. (PHVS) at $40.68 ($0.61M total) on 2026-09-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lu Peng
Published Sep 9, 2026, 3:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 3:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PHVS
Bearish
medium confidence
Mentioned
$PHVS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHVSBearishLow
01

Why it matters

The disclosed sale provides fresh data on insider sentiment for PHVS, a micro‑cap biotech.

02

Market read

First‑hand insider sale information that may influence short‑term trading decisions for PHVS.

03

What to watch

Holding after sale remains 65,179 shares, indicating continued confidence despite the partial divestiture.

Relevance 4/10Novelty 6/10Timing: same‑day filing

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$PHVSBearishMedium confidence
Context

President Lu Peng sold 15,000 shares for $610,134 via a 10b5‑1 plan on Sep 8, 2026.

Expected impact

Potential modest downside pressure over the next few days.

Evidence & confidence

The sale is sizable for a micro‑cap biotech and executed through a pre‑arranged plan, suggesting a neutral to slightly bearish impact.

Market effects

May raise concerns for other small‑cap biotech stocks if insider sales become frequent.

Limited to U.S. biotech investors; no broader regional effect.

Minimal global impact.

Counterpoint

The sale was pre‑arranged under a 10b5‑1 plan, which may not reflect current sentiment; the stock could be undervalued.

Key entities

  • Pharvaris N.V.

    Biotech firm listed on NASDAQ under ticker PHVS.

  • Lu Peng

    President of Pharvaris N.V. and reporting officer.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PHVSMed

Pharvaris reports Q3 results

Pharvaris reported a Q3 EPS of -$0.67, with cash reserves of €283M as of September 30, 2026, down from €292M at year-end 2025. The company's net loss widened to €47.4M, up from €37.1M year-over-year. Recently, Pharvaris presented at healthcare conferences and announced positive late-stage trial results for its hereditary angioedema drug, leading to an upgrade by BofA to 'Buy'.

$PHVSMedAI 8/10

Pharvaris (PHVS) Reports Q3 Results After Phase 3 Milestone

Pharvaris (PHVS) reported Q3 2026 results, highlighting FDA review of deucrictibant IR NDA with a 2027 PDUFA date. Phase 3 study data for deucrictibant XR expected in 1Q2027. NDA submission for deucrictibant XR in AE-BK attacks planned for 1H2027. Cash position of €283M as of Q3 2026. No financial figures provided for Q3.